Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

NCT00678327 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1202

Last updated 2024-05-08

No results posted yet for this study

Summary

RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before, during, and after chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment. It is not yet known whether FDG-PET/CT imaging is effective in assessing response to chemotherapy in patients with newly diagnosed Hodgkin lymphoma.

PURPOSE: This randomized phase III trial is studying FDG-PET/CT imaging to see how well it works in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma.

Conditions

Interventions

BIOLOGICAL

bleomycin sulfate

Given IV

BIOLOGICAL

filgrastim

Given subcutaneously

BIOLOGICAL

pegfilgrastim

Given subcutaneously

DRUG

cyclophosphamide

Given IV

DRUG

dacarbazine

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

etoposide

Given IV

DRUG

prednisolone

Given orally

DRUG

procarbazine hydrochloride

Given orally

DRUG

vinblastine sulfate

Given IV

DRUG

vincristine sulfate

Given IV

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER
  • Cancer Research UK & UCL Cancer Trials Centre

    collaborator OTHER
  • University College, London

    lead OTHER

Principal Investigators

  • Peter Johnson, MD · University Hospital Southampton NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-29
Primary Completion
2016-01-31
Completion
2024-05-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00678327 on ClinicalTrials.gov